Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1

Status

Completed 27Terminated 8Withdrawn 5Recruiting 3Active not recruiting 2Unknown 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2NET 1Endocrine 1

Conditions

Pancreatic Neoplasms 1Pancreatic Fistula 1Gastro-enteropancreatic neuroendocrine tumor 1

Interventions

pembrolizumab 439Carboplatin 322Nivolumab 298Cyclophosphamide 286Specimen Handling 271Magnetic Resonance Spectroscopy 259Cisplatin 250Paclitaxel 249Radiotherapy 230Dexamethasone 184Biopsy 182Gemcitabine 180durvalumab 171atezolizumab 152Doxorubicin 141Rituximab 138Lenalidomide 136Ipilimumab 134Docetaxel 132Bevacizumab 132Radiation 121Capecitabine 120Oxaliplatin 116Etoposide 116Radiosurgery 113Fluorouracil 112Pemetrexed 109fludarabine 106venetoclax 102Prednisone 97

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × pasireotide × Clear all
NCT03972488 2026-01-21

NETTER-2

Advanced Accelerator Applications

Phase 3 Active not recruiting
226 enrolled 14 charts
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor

NCT02775227 2020-08-24

HYPAR

Helsinki University Central Hospital

Phase 4 Active not recruiting
126 enrolled
Gastrointestinal

Pancreatic Fistula, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡